Search clinical trials for: Immediate Release Niacin, Extended Release Niacin, Endotoxin

Total 949 results

University of Pennsylvania

Completed

The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study (GENE)

Healthy Volunteers

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Niacin Therapy on Lipoprotein Composition and Function

Cardiovascular Disease

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Lewai Sharki Abdulaziz, MSc PhD
Al-Kindy College of Medicine

Completed

Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females

Atherogenic Dyslipidemia | Obesity Associated Disorder

Iraq
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
University of Leipzig

Completed

Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)

Coronary Disease | Hypolipoproteinemia

Germany
George Thanassoulis
Jewish General Hospital; Laval University; Quebec Heart Institute

Withdrawn

Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL)

Aortic Stenosis and Lipoprotein(a) Levels

Canada
North Texas Veterans Healthcare System
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis (ALPINE-SVG)

Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis | Intermediate Saphenous Vein Graft Lesions

United States
University of Hawaii
United States Department of Defense

Completed

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

HIV Infections | Dyslipidemia | Endothelial Dysfunction

United States
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Cortria Corporation
PPD; Pharmena North America

Completed

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Healthy

Canada
University of Miami

Terminated

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Diabetes Mellitus, Type 2 | Kidney Failure, Chronic | Hyperlipidemia

United States
Merck Sharp & Dohme LLC

Completed

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Daniel A. Siniawski
Merck Sharp & Dohme LLC

Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Coronary Artery Disease | Dyslipidemias

Argentina
Walter Reed Army Medical Center
Abbott

Terminated

Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Atherosclerosis

United States
Hannover Medical School

Completed

The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)

Metabolic Syndrome

Germany
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH (HDL Proteomics)

Myocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis

United States, Canada
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Hypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
Henry Ford Health System

Completed

Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery

Ischemic Stroke

United States
Brigham and Women's Hospital

Terminated

Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid

Inflammation | Cardiovascular Disease | Atherosclerosis | Dialysis

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

Coronary Artery Disease | Atherosclerosis | Carotid Artery Diseases

United States, Canada
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
Sheba Medical Center

Terminated

The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

Coronary Artery Disease | Dyslipidemia

Israel
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Axio Research. LLC
National Heart, Lung, and Blood Institute (NHLBI); Abbott

Terminated

Niacin Plus Statin to Prevent Vascular Events

Myocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis | Cerebrovascular Accident

United States, Canada
Kos Pharmaceuticals

Completed

Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST

Hypercholesterolemia
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Kos Pharmaceuticals

Completed

Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)

Hypercholesterolemia
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Abbott

Completed

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

United States, Canada, Puerto Rico
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Recruiting

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Migraine Prophylaxis

Bangladesh
In His Image
Kos Pharmaceuticals

Completed

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

Dyslipidemia | Hyperlipidemia | Mixed Hyperlipidemia

United States
University of Washington
Upsher-Smith Laboratories

Completed

SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia

Dyslipidemia

United States
University Hospital Schleswig-Holstein

Completed

Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)

Safety Issues | Pharmacokinetic

Germany
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
McGill University Health Centre/Research Institute...
CIHR Canadian HIV Trials Network

Completed

Niacin on Immune Activation : a Proof-of-concept Study

HIV

Canada
Abbott

Completed

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

Dyslipidemia

United States
Merck Sharp & Dohme LLC

Completed

Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED) (MCAT)

Carotid Atherosclerosis
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Kos Pharmaceuticals

Completed

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC

Intermittent Claudication | Peripheral Vascular Disease

United States
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Kos Pharmaceuticals

Completed

Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication

Intermittent Claudication | Peripheral Vascular Disease
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
NYU Langone Health

Completed

A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall

Attention Deficit Hyperactivity Disorder

United States

3

Subscribe